Wugen

#EHA2024 Data: Wugen presents positive Phase 2 results for WU-CART-007. During today’s oral presentation at the European Hematology Association (EHA) 2024 Hybrid Congress, researchers shared positive Phase 2 results for our investigational allogeneic, off-the-shelf anti-CD7 CAR-T therapy in patients with relapsed/refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). Learn more about what these WU-CART-007 findings could mean for patients with hard-to-treat blood cancers: https://bit.ly/4aXdRi4 #celltherapy #research #biotechnology #WashU

BIOTECH NEWS: Wugen announced RMAT and PRIME designations to accelerate regulatory reviews for its investigational, off-the-shelf allogeneic CAR-T cell therapy, WU-CART-007, in the U.S and E.U. These designations follow FDA and EMA review of Wugen studies, including its global Phase 1/2 study. The newest Phase 2 data will be presented at European Hematology Association (EHA)'s 2024 meeting in June. Learn more about todays’ news and WU-CART-007: https://bit.ly/3wPuRIX #EHA2024 #cancer #celltherapy

BIOTECH NEWS: Wugen announced RMAT and PRIME designations to accelerate regulatory reviews for its investigational, off-the-shelf allogeneic CAR-T cell therapy, WU-CART-007, in the U.S and E.U. These designations follow FDA and EMA review of Wugen studies, including its global Phase 1/2 study. The newest Phase 2 data will be presented at European Hematology Association (EHA)'s 2024 meeting in June. Learn more about todays’ news and WU-CART-007: https://bit.ly/3wPuRIX #EHA2024 #cancer #celltherapy

We’re hiring! Wugen is seeking an exceptional and highly motivated candidate to join our growing QA team based in St. Louis, MO or San Diego, CA. The person in this role will be responsible for helping maintain Wugen's quality systems through electronic document management. Learn more: https://lnkd.in/df2XrytM

Thrilled to announce our new agreement with Cellipont Bioservices, a leading cell therapy contract development and manufacturing organization (CDMO), for the manufacturing of Wugen’s allogeneic CAR-T cell therapies being studied for hematological and solid tumor malignancies. #oncology #cancerresearch #biotechnology

Today, we had the privilege of sharing the latest data from our ongoing Phase 1/2 trial of WU-CART-007 at the American Society of Hematology Annual Meeting & Exposition. #ASH23 Initial favorable results underscore our ongoing progress in advancing Wugen’s mission to leverage cutting-edge CAR-T therapies for difficult-to-treat blood cancers. Learn more about the latest data on WU-CART-007 here: https://bit.ly/3tnauB8 #clinicaltrials #immunotherapy #oncology #biotechnology

We are excited to join hematology experts at the American Society of Hematology Annual Meeting & Exposition to share our newest data on potential new treatments for hard-to-treat blood cancers. #ASH23 We’re presenting oral and poster sessions about data from our two investigational allogeneic cell therapies for challenging hematologic cancers – explore the details in our curtain raiser release: https://lnkd.in/gPmE9eaR #biotechnology #celltherapy #immunotherapy #oncology  

Today, we unveiled four new abstracts from new clinical and preclinical studies to be presented at the 65th American Society of Hematology Annual Meeting & Exposition. Clinical data presented will highlight the latest findings on WU-CART-007 in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T ALL)/lymphoblastic lymphoma (LBL). In addition, results from three pre-clinical studies of WU-NK-101, an allogeneic memory natural killer (NK) cell therapy, in patients with acute myeloid #leukemia (#AML) will be presented. Read our announcement to learn more: https://lnkd.in/gPmE9eaR #ASH23 #oncology #cancerresearch #biotechnology

We're looking forward to the Society for Immunotherapy of Cancer (SITC) Annual Meeting, where we'll share new preclinical data for WU-NK-101, an allogenic memory NK cell product demonstrating engagement of the adaptive immune response and synergy with checkpoint inhibitors to overcome immune evasion by solid tumors. These data provide a strong rationale for exploring the combination of WU-NK-101 with immune checkpoint inhibitors to improve patient outcomes. #SITC23 #onology #biotechnology #cancerresearch